Title:
MARKER FOR DETERMINING SENSITIVITY OF IRINOTECAN-CONTAINING ANTI-CANCER AGENT THERAPY
Document Type and Number:
WIPO Patent Application WO/2019/188446
Kind Code:
A1
Abstract:
Provided is a new marker for determining the sensitivity of an anti-cancer agent. The marker is composed of at least one molecule selected from 5A4CR, ALA, ASP, CYS, CSSG, GLC3P, HIS, ILE, LEU, LYS, METSF, N6TLY, N6ALY, OCTA, SER, TUCA, THR, TRP, TYR, and VAL. Provided is a marker for determining the sensitivity of an anti-cancer agent including irinotecan, SN-38, or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof. Provided is a marker for determining the sensitivity of an anti-cancer agent, wherein the marker is composed of at least one molecule selected from 3IND, 4OVAL, 5A4CR, ALA, BENZA, CREAT, CSSG, DECNA, GABB, GLC3P, HYPTA, LYS, METSF, N8ASR, QUINA, SARCO, TMNO, and VAL, and includes irinotecan, SN-38, or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof.
Inventors:
SUGIMOTO SHINJI (JP)
SASAKI NOBUNARI (JP)
TANIGAWARA YUSUKE (JP)
SASAKI NOBUNARI (JP)
TANIGAWARA YUSUKE (JP)
Application Number:
PCT/JP2019/010963
Publication Date:
October 03, 2019
Filing Date:
March 15, 2019
Export Citation:
Assignee:
UNIV KEIO (JP)
YAKULT HONSHA KK (JP)
YAKULT HONSHA KK (JP)
International Classes:
G01N33/68; A61K31/4745; A61K31/513; A61K31/519; A61K39/395; A61K45/00; A61P35/00; A61P43/00; G01N33/15; G01N33/50
Domestic Patent References:
| WO2016031816A1 | 2016-03-03 | |||
| WO2009096189A1 | 2009-08-06 | |||
| WO2009096189A1 | 2009-08-06 | |||
| WO2011052750A1 | 2011-05-05 | |||
| WO2012127984A1 | 2012-09-27 | |||
| WO2013125675A1 | 2013-08-29 |
Other References:
SHOICHI HAZAMA : "effects of colorectal cancer chemotherapy by new genetic polymrophism analysis and development of toxic prediction system", THE JAPANESE JOURNAL OF GASTROENTEROLOGICAL SURGERY, vol. 42, no. 7, 1 July 2009 (2009-07-01), pages 955, XP055736873, ISSN: 0386-9768, DOI: 10.5833/jjgs.42.951
HARA MASAYASU; NAGASAKI TAKAYA; SHIGA KAZUYOSHI; TAKAHASHI HIROKI; TAKEYAMA HIROMITSU: "High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab", SURGERY TODAY, vol. 47, no. 4, 2060822, pages 483 - 489, XP036174920, ISSN: 0941-1291, DOI: 10.1007/s00595-016-1404-7
TOURNIGAND C. ET AL.: "FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randamized GERCOR Study", JCO, vol. 22, no. 2, 2004, pages 229 - 37
J PROTEOME RES., vol. 2, no. 5, September 2003 (2003-09-01), pages 488 - 94
METABOLOMICS, vol. 6, no. 1, March 2010 (2010-03-01), pages 78 - 95
METABOLOMICS, vol. 9, no. 2, April 2013 (2013-04-01), pages 444 - 453
See also references of EP 3779451A4
HARA MASAYASU; NAGASAKI TAKAYA; SHIGA KAZUYOSHI; TAKAHASHI HIROKI; TAKEYAMA HIROMITSU: "High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab", SURGERY TODAY, vol. 47, no. 4, 2060822, pages 483 - 489, XP036174920, ISSN: 0941-1291, DOI: 10.1007/s00595-016-1404-7
TOURNIGAND C. ET AL.: "FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randamized GERCOR Study", JCO, vol. 22, no. 2, 2004, pages 229 - 37
J PROTEOME RES., vol. 2, no. 5, September 2003 (2003-09-01), pages 488 - 94
METABOLOMICS, vol. 6, no. 1, March 2010 (2010-03-01), pages 78 - 95
METABOLOMICS, vol. 9, no. 2, April 2013 (2013-04-01), pages 444 - 453
See also references of EP 3779451A4
Attorney, Agent or Firm:
THE PATENT CORPORATE BODY ARUGA PATENT OFFICE (JP)
Download PDF:
Previous Patent: SUPPORTING FRAME FOR PELLICLE, PELLICLE, METHOD FOR MANUFACTURING SAME, EXPOSURE MASTER USING SAME, ...
Next Patent: OPTICAL LENS
Next Patent: OPTICAL LENS